Researchers from the United States assessed the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity in patients with curatively resected colon cancer.
The research team performed a cohort study within a large, randomized adjuvant chemotherapy trial of 3759 patients, with high-risk stage II and stage III colon cancer treated between 1988 and 1992.
Within the cohort, the researchers identified 287 patients with diabetes mellitus.
- diabetics = 6 years
- nondiabetics = 11.3 years.
|Journal of Clinical Oncology|
Median duration of follow-up was 9.4 years.
The team analyzed differences in overall survival, and colon cancer recurrence.
They also assessed treatment-related toxicity between patients with diabetes, and those without diabetes.
At 5 years, patients with diabetes mellitus experienced a significantly worse disease-free and recurrence-free survival, compared to patients without diabetes.
The researchers determined that median survival was 6 years for diabetics and 11.3 years for nondiabetics.
Patients with diabetes had a 42% increased risk of death from any cause, and a 21% increased risk for recurrence after adjustment for other predictors of colon cancer outcome.
Treatment-related toxicities were similar between the 2 groups, although patients with diabetes experienced an increase in treatment-related diarrhea.
Dr Jeffrey Meyerhardt’s team concluded, “Patients with diabetes mellitus and high-risk stage II and stage III colon cancer experienced a significantly higher rate of overall mortality and cancer recurrence, even after adjustment for other predictors of colon cancer outcome”.
“These results underscore the need for further research to understand the mechanism that underlies this relation.”